Given the known differences between the clinical trial environment and routine clinic setting, we sought to explore the efficacy and toxicity of neoadjuvant HER2 doublet in combination with chemotherapy within the practice of a tertiary referral NHS cancer centre in the UK. This evidence concerns the gene ERBB2 and cancer.